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PURPOSE. To elucidate the role of the glial glutamate transporter GLAST, in the regulation of retinal
function.
METHODS. Antisense oligonucleotides to GLAST were injected intravitreally into the left eye of
Wistar rats. Sense oligonucleotides (control) were injected into the right eye over a period of 3
days. Scotopic flash electroretinograms were recorded over a 20-day period. To assay whether the
antisense oligonucleotides caused a reduction in the expression or the activity of GLAST, retinas
were exposed to D-aspartate, a nonendogenous substrate of glutamate transporters. The retinas
were immunolabeled with specific antibodies for D-aspartate. Retinal GLAST and glutamate distri-
butions also were determined immunocytochemically.
RESULTS. Antisense oligonucleotides markedly suppressed the electroretinogram b-wave, whereas
sense oligonucleotides had no significant effect. Significant changes in the electroretinogram were
apparent 5 days after injection of antisense oligonucleotide and were sustained for at least 20 days.
A marked reduction of D-aspartate uptake into Mu¨ller cells of retinas that had been exposed to the
antisense oligonucleotides 5 days previously suggests a reduction of GLAST activity. The retinas,
however, displayed no evidence of excitotoxic neuronal degeneration, and the distribution of
glutamate was unaffected by antisense treatment.
CONCLUSIONS. The observed lack of neuronal degeneration suggests that reduced glutamate uptake
into Mu¨ller cells does not cause excitotoxic tissue damage. A direct perturbation of glutamatergic
signaling is more likely, because the rapid clearance of glutamate is necessary for light elicited
signaling between photoreceptors and bipolar cells. This suggests that GLAST is essential for the
maintenance of normal retinal transmission. (Invest Ophthalmol Vis Sci. 2000;41:585–591)
Glutamate is the major excitatory neurotransmitter inthe retina.1,2 The homeostasis of extracellular levels ofglutamate is critical for retinal function under normal
and pathologic conditions. This task is performed by a number
of excitatory amino acid transporters (EAATs) localized to
neuronal and glial elements. Five distinct human EAATs
(EAAT1–5) have been cloned.3–5 Rodent homologues of EAATs
1 to 4 have been cloned, and EAAT1 (GLAST), EAAT2 (GLT-1),
and EAAT 3 (EAAC-1) have been identified by immunocyto-
chemistry in the rodent retina.6,7 GLT-1 is predominantly lo-
calized to astrocytes in the brain, but immunocytochemical
analysis of the rat retina has shown GLT-1 to be associated with
cones and cone bipolar cells, not glial elements.8 EAAC-1 is
associated with rat retinal neurons whose processes ramify in
the inner plexiform layer, principally amacrine cells.9 The
cellular localization of EAAT5 in the retina has not been estab-
lished unequivocally. EAAT5 has been reported to be associ-
ated with Mu¨ller cells in the salamander retina10 and photore-
ceptors in the rat retina.11 GLAST is exclusively associated with
Mu¨ller cells rather than neurons,6,12 but GLAST-immunoposi-
tive Mu¨ller cell processes do ensheath the somata of most
photoreceptors, bipolar cells, and ganglion cells.6 Autoradio-
graphic studies indicate that Mu¨ller cells dominate total retinal
glutamate transport, utilizing GLAST.13–15 GLAST is involved in
the neuron–glia glutamate–glutamine cycle whereby Mu¨ller
cells take up neuronally released glutamate and convert the
glutamate to glutamine. Neuronal function is thought to be
dependent on the availability of glutamine released by the
Mu¨ller cells.16
Because specific inhibitors of glutamate transport do not
exist, we investigated the role of GLAST by the inhibition of its
synthesis with antisense oligonucleotides. Similar techniques
have been used to knockout GLAST in the striatum and hip-
pocampus.17 Furthermore, antisense administration has been
shown to be a highly effective approach for the regulation of
protein expression in the retina.18,19
MATERIALS AND METHODS
Animals
Female Wistar rats (200–250 g) were used for all experiments.
All animals were treated in accordance with the ARVO State-
ment for Use of Animals in Ophthalmic and Vision Research
and were within the ethical guidelines of the Australian Na-
tional Health and Medical Research Council and The University
of Queensland.
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Oligonucleotides
Antisense and sense oligonucleotides corresponding to nucle-
otides 212 to 15 of the cloned rat glutamate transporter,
GLAST5 were commercially synthesized (Pacific Oligos, Bris-
bane, Australia). The antisense sequence GTTGCTTTTTGT-
CATATTTTATCTTTC and the sense sequence GAAAGATA-
AAATATGACAAAAAGCAAC were protected by the use of
phosphorothioate linkages between each of the bases. This
modification also increases lipid solubility. The left eye of each
rat was injected on day 1 and day 3 of the experiment with 2
ml of sterile water containing 30 mg of antisense oligonucleo-
tide. The right eye served as a control and was injected with
sense oligonucleotide.
Electroretinography
Rats were anesthetized with an intramuscular injection of ket-
amine (100 mg/kg) and xylazine (12 mg/kg), placed in a ste-
reotaxic frame, and maintained at 37°C with a homeothermic
blanket. The rat’s pupils were dilated with 1% tropicamide, and
the corneas kept moist with carmellose sodium (Celluvisc;
Allergan, Sydney, Australia). The animals were then allowed to
dark-adapt for 30 minutes before the recording of scotopic
flash electroretinograms (ERG). A platinum wire loop was
placed on each cornea to act as the recording electrode, and a
reference electrode was connected to each ear. Ground elec-
trodes were attached to the animal’s back. A xenon strobe light
placed 0.5 m in front of the animal presented the flash stimulus
at 0.25 Hz. Eight consecutive responses were amplified and
averaged using a MacLab/2e bioamplifier/data recorder run-
ning “Scope” software (AD Instruments, Sydney, NSW, Austra-
lia). The peak amplitudes of the a- and b-waves of the electro-
retinogram were determined before the injection of sense or
antisense oligonucleotides and at 5 (n 5 13), 10 (n 5 7), and
20 (n 5 5) days after injection. The a-wave amplitude was
measured from the baseline to the trough of the a-wave re-
sponse, and the b-wave amplitude was measured from the
trough of the a-wave to the peak of the b-wave. Data are
expressed as the mean wave amplitude 6 SEM (mV). Two-
factor repeated-measures analysis of variance (ANOVA) was
performed to compare the responses from antisense-treated
retinas with those from sense-treated control retinas over the
20-day period. Implicit times were measured from the flash
stimulus to the peak of the b-wave response.
Glutamine Effects on the Suppressed ERG
After the suppression of the ERG by antisense oligonucleo-
tides, the effect of an intraocular injection of glutamine was
investigated. Glutamine (4 mM in 2 ml saline) was injected 5
days after the first GLAST antisense injection. Electroretino-
grams were recorded 5 and 20 minutes after glutamine admin-
istration.
Immunocytochemistry for GLAST
Five days after the initial injection of antisense or sense oligo-
nucleotides, rats were killed by an overdose of sodium pento-
barbital [200 mg/kg intraperitoneally (IP)]. Isolated retinas
were immersion fixed for 90 minutes with 4% paraformalde-
hyde in 0.1 M phosphate buffer, pH 7.4. The fixed retinas were
embedded in 4% agar and 30-mm-thick transverse sections cut
on a Vibratome (T.P.I., St. Louis, MO). Free-floating sections
were labeled with antisera raised in rabbit against the N termi-
nus of GLAST6 and diluted 1:100,000 in phosphate-buffered
saline containing 0.2% Triton X-100 plus 5% normal horse
serum. Labeling was detected using donkey anti-rabbit (Amer-
sham, Sydney, NSW, Australia) diluted 1:300, followed by
streptavidin–biotin–horseradish peroxidase complex (Amer-
sham) diluted 1:300. Diaminobenzidine was used as a chromo-
gen.
D-Aspartate Uptake and Immunolabeling
Rats were killed by an injection of sodium pentobarbital (200
mg/kg IP), and the eyes were enucleated immediately. Isolated
retinas were incubated in vitro at 37°C for 90 minutes in
oxygenated Ames medium containing D-aspartate (50 mM), a
nonendogenous substrate of glutamate transporters that can be
detected by immunocytochemistry.20 The retinas were then
fixed with 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH
7.2) for 16 hours, dehydrated, and embedded in Araldite (Pro-
SciTech, Thuringowa, QLD, Australia) resin. Semi-thin sections
(0.5 mm thick) of retina were then immunolabeled with spe-
cific antibodies for D-aspartate (1:30,000 dilution)6 or gluta-
mate (1:300,000) using our standard techniques with previ-
ously characterized antisera.21
Morphometric Analysis
Semi-thin sections of retina obtained approximately 2 mm
superior to the optic disc were stained with toluidine blue,
viewed on a Zeiss Axioskop microscope (Oberkochen, Ger-
many), and digitally imaged. The thickness of the inner plexi-
form layer, the inner nuclear layer, the outer nuclear layer, and
the total retinal thickness were analyzed using NIH Image
software. The retinas of six rats were measured, and a paired
t-test was used to compare values obtained from antisense-
treated eyes with those from control, sense-treated eyes.
RESULTS
GLAST Immunocytochemistry
Five days after the initial injection of GLAST sense oligonucle-
otide, the distribution and intensity of GLAST immunoreactiv-
ity was indistinguishable from that seen in normal adult rat
retinas (Fig. 1A, 1B). Intense staining was seen in the glial
elements of the retina, particularly the Mu¨ller cell end feet
forming the outer limiting membrane. Three distinct bands of
GLAST immunolabeling were seen in the inner plexiform layer,
and heavy labeling of the outer plexiform layer, corresponding
to the lateral processes of the Mu¨ller cells. Moreover, Mu¨ller
cell processes ramifying through the inner nuclear layer en-
sheath the bipolar cell perykarya. Positively labeled radial Mu¨l-
ler cell processes could be seen throughout the outer nuclear
layer. No GLAST-like immunoreactivity was evident in neuronal
elements of the retina.
The intensity of GLAST immunoreactivity was drasti-
cally reduced by the injection of GLAST antisense oligonu-
cleotides, indicating that knockdown of GLAST was success-
ful (Fig. 1C). After 5 days, the labeling in the plexiform
layers and that of the Mu¨ller cell end feet was very weak, but
still observable. Weakly labeled radial Mu¨ller cell processes
also could be seen in the outer nuclear layer. It was no
longer possible, however, to distinguish the Mu¨ller cell
processes ensheathing the bipolar cell bodies in the inner
nuclear layer, where all GLAST expression appeared to be
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suppressed. Furthermore, antisense oligonucleotide treat-
ment significantly reduced GLAST labeling of astrocytes/
Mu¨ller cell end feet in the ganglion cell layer/nerve fiber
layer, when compared with sense treated control retinas.
GLAST Activity
The activity of the GLAST transporter was assessed before and
after oligonucleotide treatment by measuring the accumulation
of D-aspartate by immunocytochemistry, since D-aspartate is a
substrate for all glutamate transporters. No endogenous D-
aspartate immunolabeling is observed in retinas that are fixed
immediately and had not been exposed to exogenous D-aspar-
tate.6 Following incubation with D-aspartate of normal retinas
that had not been treated with oligonucleotides, D-aspartate
was exclusively accumulated into the Mu¨ller cells (Fig. 2A).
The strongest labeling occurred in the Mu¨ller cell perykarya,
the end feet in the nerve fiber layer, and the outer limiting
membrane. No D-aspartate immunoreactivity was observed in
any neuronal cells. A similar pattern of D-aspartate accumula-
tion by the Mu¨ller cells was seen in retinas that had been
injected with sense oligonucleotides 5 days previously (Fig. 2B).
Five days after the first intraocular antisense injection, the
pattern of D-aspartate accumulation and immunoreactivity al-
tered significantly. The transporter substrate accumulated in
the photoreceptors, bipolar cells, and a few ganglion cells,
whereas no significant D-aspartate immunolabeling could be
observed in the glial Mu¨ller cells. The bipolar cell terminals in
the ganglion cell layer displayed particularly intense D-aspar-
tate staining (Fig. 2C). Ten days after the initial injection of
GLAST antisense, the Mu¨ller cells regained their ability to
accumulate D-aspartate. Although the D-aspartate localized to
the Mu¨ller cells, the intensity of labeling was much weaker
than that of the preinjected or control sense-treated retinas.
The D-aspartate appeared to be transported to the glial cell
bodies, which stained more intensely than their radial pro-
cesses and end feet. Very little D-aspartate immunoreactivity
could be seen in neuronal elements 10 days after antisense
oligonucleotide treatment (Fig. 2D).
Glutamate Immunocytochemistry
In sense-injected control retinas, glutamate immunoreactivity
was observed in the inner segments of photoreceptors, as well
as in bipolar cells and their processes in the inner plexiform
layer (Fig. 3A). The somata of ganglion cells also were strongly
labeled for glutamate. No labeling was observed in the pro-
cesses or somata of Mu¨ller cells. The distribution and intensity
of glutamate labeling was unaffected by the administration of
GLAST antisense, when observed 5 or 10 days after the first
injection of oligonucleotide (Fig. 3B).
Morphometric Analysis
Table 1 shows that retinal thickness was not affected by GLAST
antisense treatment. No significant neurodegeneration or
edema was observed by morphometric analysis of the inner
plexiform layer, inner nuclear layer, and outer nuclear layer
performed 10 days after the initial injection of oligonucleotide.
Histologic observation of toluidine blue–stained 0.5-mm
sections of retina revealed little difference between the anti-
sense- and sense-treated control retinas. All neurons appeared
to be normal, with no evidence of excitotoxic neuronal dam-
age. Swelling of the Mu¨ller cells was, however, evident 10 days
after the antisense treatment and can be seen clearly in Figures
3B and 4B.
Electroretinography
The intraocular injection of GLAST sense oligonucleotide did
not affect the waveform of the scotopic flash ERG. It can be
FIGURE 1. Rat retinas immunolabeled for GLAST. (A) In a normal
control retina, labeling is associated with Mu¨ller cells. Radial processes
(large arrow) and end feet in the outer nuclear layer (ONL) are
labeled, as is a dark band in the outer plexiform layer (OPL). Cells in
the inner nuclear layer (INL) are surrounded by GLAST-immunoreac-
tive processes. Three bands (small arrows) of lateral processes within
the inner plexiform layer (IPL) are immunolabeled for GLAST. (B) The
pattern of GLAST-immunoreactivity is not affected by the administra-
tion of GLAST sense oligonucleotides. (C) Five days after GLAST anti-
sense treatment, the expression of GLAST is drastically reduced. Weak
GLAST immunoreactivity can be seen in the OPL and IPL.
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seen in Figure 5 that neither the amplitude nor the latency of
the positive-going b-wave were altered. Single-factor ANOVA
showed no significant change in the b-wave amplitude over 20
days after the injection (F(3) 5 1.10, P 5 0.36). Similarly, the
negative-going a-wave was not affected by the administration
of sense oligonucleotides (F(3) 5 0.82, P 5 0.49). The sense-
injected eye was subsequently used as the control for the
contralateral antisense-injected eye in all experiments.
Figure 6 shows that the b-wave amplitudes of eyes that
had been injected with antisense oligonucleotides to GLAST
were significantly reduced when compared with ERGs re-
corded from sense-treated control eyes (two-factor repeated-
measures ANOVA, F(78) 5 7.80, P 5 0.007). Post hoc, paired
t-tests revealed a significant (P , 0.01) suppression of the
b-wave at 5, 10, and 20 days after injection. Five days after the
first antisense injection, the mean b-wave amplitude was 169 6
31 mV (n 5 13) compared with 342 6 64 mV (sense control);
at 10 days the mean b-wave was 192 6 49 mV (274 6 71 mV
sense control, n 5 7), and after 20 days, the amplitude was
reduced to 107 6 32 mV (283 6 88 mV sense control, n 5 5).
The implicit time of the b-wave component was not af-
fected by the intraocular injection of GLAST antisense oligonu-
cleotides (F(78) 5 0.00004, P 5 0.995). Furthermore, the ap-
parent decrease in the a-wave amplitude after administration of
GLAST antisense oligonucleotides seen in Figure 7 is not sta-
tistically significant when compared with sense-treated control
values (F(78) 5 0.85, P 5 0.36).
The intraocular injection of glutamine (4 mM) after anti-
sense treatment had no apparent effect on the amplitude nor
on the waveform of the electroretinogram when recorded 5
minutes or 20 minutes after administration (Fig. 8).
DISCUSSION
We have recently shown that changes in GLAST expression are
temporally associated with periods of cellular differentiation
FIGURE 3. Glutamate immunoreactivity in the rat retina. (A) In sense-
injected control retina, glutamate is associated with the inner segments
of photoreceptors (PR), bipolar cells (BP), and ganglion cells (G). (B)
The pattern of glutamate labeling is not altered when observed 5 or 10
days after the injection of GLAST antisense oligonucleotides. The
inhibition of GLAST synthesis does, however, cause swelling of the
Mu¨ller cells (M). Outer nuclear layer, ONL; inner plexiform layer, IPL.
TABLE 1. Morphometric Analysis of Retinal Layers 10 Days after
Oligonucleotide Administration
Layer
Thickness (mm)
n PSense Antisense
IPL 38 6 3 40 6 2 6 0.61 (NS)
INL 29 6 2 32 6 3 6 0.42 (NS)
ONL 40 6 5 45 6 3 6 0.37 (NS)
Total 138 6 12 159 6 11 6 0.23 (NS)
Values are means 6 SEM. NS, not statistically significant (P .
0.05).
FIGURE 2. Rat retina exposed to D-
aspartate (50 mM, in vitro) and then
immunolabeled for the presence of
D-aspartate. (A) D-Aspartate is taken
up exclusively by Mu¨ller cells (M) in
control retinas. (B) The pattern of
D-aspartate accumulation is not af-
fected by the administration of
GLAST sense oligonucleotides. (C)
Five days after the inhibition of
GLAST synthesis by antisense oligo-
nucleotides, there is a marked reduc-
tion in D-aspartate uptake by Mu¨ller
cells and the appearance of D-aspar-
tate in photoreceptors (PR), bipolar
cells (BP), and ganglion cells (G). (D)
Ten days after antisense administra-
tion, weak D-aspartate uptake and
immunolabeling is associated with
Mu¨ller cells (M). Outer nuclear layer,
ONL; inner nuclear layer; INL; inner
plexiform layer, IPL.
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and synaptogenesis.6 This study demonstrates that electrical
function of the adult rat retina is also dependent on functional
GLAST transporters. Because of the unavailability of specific
glutamate transporter inhibitors, antisense oligonucleotides of
GLAST were used to suppress the synthesis of new retinal
GLAST protein in vivo. Figure 1 shows that this approach
successfully reduces the expression of GLAST in the retina, as
evinced by immunocytochemistry. Moreover, the small degree
of variation between the ERGs recorded from different animals
(Fig. 6) suggests that this intraocular antisense approach is
particularly applicable to the targeting of glial cell proteins, as
astrocytes and Mu¨ller cell end feet form the vitreous/retinal
barrier. The suppression of retinal GLAST expression has pre-
viously been shown in a knockout mouse model,22 but the
method of direct intraocular injection of oligonucleotides used
in this study targets the effect to the retina, eliminating the
possibility of global effects.
We demonstrate directly that the inhibition of GLAST
synthesis alters the capacity of Mu¨ller cells to transport D-
aspartate, and by inference, glutamate. Five days after the
antisense oligonucleotide injection, the Mu¨ller cells lose all
ability to accumulate exogenous D-aspartate (Fig. 2C). Mu¨ller
cell processes ensheath retinal neurons and provide a physical
barrier that normally prevents the uptake of D-aspartate into
neurons, even though the neurons possess the glutamate trans-
porters, GLT-1 and EAAC-1.8,9 Inhibition of Mu¨ller cell GLAST
synthesis removes the barrier to neuronal D-aspartate uptake
and results in the pattern of D-aspartate labeling seen in Figure
2C. D-aspartate is now accumulated into photoreceptors, bipo-
lar cells, and ganglion cells. Moreover, the lack of detectable
D-aspartate uptake by Mu¨ller cells supports the view that
GLAST is the overwhelmingly predominant glutamate trans-
porter in Mu¨ller cells.6 It is unlikely that any other glutamate
transporters, such as EAAT5, if expressed in Mu¨ller cells,10
make any significant functional contribution to glutamate ho-
meostasis by the Mu¨ller cells. The accumulation of D-aspartate
by neurons rather than Mu¨ller cells after the antisense admin-
istration is, however, transient. Ten days after the first oligo-
FIGURE 4. Semi-thin sections of rat retina stained with toluidine blue.
(A) Ten days after GLAST sense oligonucleotide administration, the
histology of the outer retina appears to be normal. (B) Ten days after
the injection of GLAST antisense oligonucleotide, edematous Mu¨ller
cells (M) are apparent in the inner nuclear layer (INL), and their
swollen processes are evident in the outer nuclear layer (ONL).
FIGURE 5. Scotopic electroretinograms (ERG) recorded before (Pre-
injection) and 5, 10, and 20 days after the intraocular injection of either
GLAST sense or antisense oligonucleotides. Administration of GLAST
sense has no effect on the ERG. Five days after antisense administra-
tion, the ERG b-wave is reduced. The b-wave suppression remains for
at least 20 days.
FIGURE 6. The effect of GLAST sense and antisense oligonucleotides
on the ERG b-wave amplitude. The administration of GLAST antisense
significantly reduces the ERG b-wave amplitude when compared with
the GLAST sense-treated contralateral control eye response. Each bar
represents the mean 6 SEM. *Statistically significant (P , 0.01) differ-
ence between the mean antisense and sense responses.
FIGURE 7. The effect of GLAST sense and antisense oligonucleotides
on the ERG a-wave amplitude. GLAST antisense oligonucleotides do
not have a statistically significant effect on the a-wave amplitude when
compared with responses obtained from sense-treated control retinas.
Each bar represents the mean 6 SEM.
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nucleotide injection (and 7 days after the second, final injec-
tion), exogenous D-aspartate is accumulated weakly into
Mu¨ller cells (Fig. 2D). This observation is indicative of a return
of GLAST synthesis.
The onset of GLAST synthesis by Mu¨ller cells does not,
however, result in a return of normal retinal function. The ERG
b-wave, which is significantly attenuated 5 days after antisense
administration, remains suppressed for at least 20 days (see Fig.
6). The suppression of the ERG b-wave, but not of the a-wave,
observed in this study is in agreement with the electrophysio-
logical findings reported by Harada et al.,22 who used a GLAST
knockout mutant mouse model. A number of possibilities
could explain the inhibition of the ERG b-wave resulting from
the perturbation of glutamate homeostasis. Glutamatergic neu-
rons such as photoreceptors and bipolar cells are dependent
on a supply of glutamine from Mu¨ller cells to synthesize glu-
tamate for neurotransmission.16 This glutamine is synthesized
by the glial enzyme, glutamine synthetase, from accumulated
glutamate. It is a possibility that after the inhibition of GLAST
expression, the supply of glutamine to the neurons is cut off
because of the unavailability of its precursor glutamate in the
Mu¨ller cells. It is unlikely, however, that inadequate glutamine
availability is the cause of the ERG b-wave suppression re-
ported here. Intraocular glutamine administration had no effect
on the ERG when injected on day 5, that is, when the ERG was
maximally suppressed (Fig. 8). Moreover, the pattern of gluta-
mate immunoreactivity is not altered by GLAST antisense treat-
ment (Fig. 3). Thus, the suppression of the ERG b-wave is not
likely to be due to an exhaustion of neuronal glutamate. The
specificity of the oligonucleotides ensures that the neuronally
localized glutamate transporters are unaffected and thus re-
main capable of taking up sufficient glutamate to maintain
intracellular neuronal glutamate levels (Figs. 2, 3). Further-
more, because D-aspartate is transported into photoreceptor
and bipolar cells, but not into Mu¨ller cells, 5 days after anti-
sense administration (Fig. 2), it is likely that neuronal reuptake
rather than Mu¨ller cell glutamate glutamine cycling16 is respon-
sible for replenishing the transmitter pool of glutamate. A more
plausible explanation for the observed physiological effects is
an increase in the concentration of extracellular glutamate due
to compromised transporter activity. The rapid removal of
glutamate from the extracellular space is vital for neurotrans-
mission from photoreceptors to bipolar cells. A rise in extra-
cellular glutamate concentration at this synapse, which could
occur in the absence of GLAST activity, would block ON-
bipolar cell depolarization and hence inhibit the generation of
the ERG b-wave.23 However, this idea is complicated by the
finding that the ERG b-wave remains suppressed for 20 days
after the antisense treatment, even though D-aspartate, and by
inference glutamate, uptake into Mu¨ller cells returns after 10
days. Although morphometric analysis revealed no significant
changes in retinal thickness, histologic alterations of Mu¨ller
cells could be seen clearly after antisense administration (Fig.
4). Although the sustained increase in extracellular glutamate
concentration did not result in obvious excitotoxic neuronal
cell death, the consequent Mu¨ller cell edema seen in Figure 4
could be contributing to the long-term b-wave suppression,
probably as a result of compromised potassium siphoning
capabilities.24 Mu¨ller cell swelling in response to exogenously
applied glutamate recently has been reported in rat retinal
segments ex vivo.25 These authors also report no associated
excitotoxic neuronal damage unless a very high concentration
(3 mM) of glutamate is applied. Thus, the neuronal uptake of
glutamate that occurs after the knockdown of GLAST (Fig. 2)
probably maintains the extracellular glutamate concentration
below excitotoxic levels but above physiological levels neces-
sary for normal signaling between photoreceptors and bipolar
cells. These results strongly support and extend the emerging
literature, which shows that glial cells play a vital role in
mediating glutamatergic neurotransmission.16,17,22 The direct
demonstration of a functional perturbation, as evinced by dis-
ruption of the ERG, validates this role in the retina. Conversely,
these data also demonstrate that glial cells may exhibit long-
term damage (as shown by their swelling) if they are prevented
from facilitating normal retinal neurotransmission. Clearly, the
association between retinal glia and neurotransmission re-
quires significant consideration when elucidating the funda-
mental basis of clinically significant pathologic states. Such
conditions include ischemic retinal damage after central retinal
artery/vein occlusion, which is thought to be associated with
elevated extracellular glutamate; in glaucoma, there is evi-
dence for perturbed glutamate homeostasis, as demonstrated
by elevated levels of glutamate in Mu¨ller cells and in the
vitreous humor.26–31
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